Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients
- 19 April 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 61 (8), 1885-1893
- https://doi.org/10.1080/10428194.2020.1749605
Abstract
The MAF translocations, t(14;16) and t(14;20), are considered as adverse prognostic factors based on few studies with small sample sizes. We report on their prognostic impact in a large group of 254 patients – 223 (87.8%) with t(14;16) and 31 (12.2%) with t(14;20). There were no intergroup differences in survival estimates. Median progression-free survival was 16.6 months for t(14;16) and 24.9 months for t(14;20) (p = 0.28). Median overall survival (OS) was 54.0 months and 49.0 months, respectively (p = 0.62). Median OS in patients who underwent double autologous stem cell transplantation (ASCT) was 107.0 months versus 60.0 months in patients who received single ASCT (p < 0.001). ISS 3 was associated with shorter OS (HR = 1.89; 95% CI 1.24–3.19; p = 0.005) in Cox analysis. Our study suggests that t(14;20) should be considered as an adverse factor of equal prognostic implication to t(14;16).This publication has 21 references indexed in Scilit:
- The Evolution of Prognostic Factors in Multiple MyelomaAdvances in Hematology, 2017
- Genomic Aberrations in Multiple MyelomaPublished by Springer Science and Business Media LLC ,2016
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working GroupJournal of Clinical Oncology, 2015
- Multiple myelomaThe Lancet, 2015
- Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013Mayo Clinic Proceedings, 2013
- The prognostic significance of cytogenetics and molecular profiling in multiple myelomaCancer Genetics, 2011
- The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significanceHaematologica, 2010
- Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working GroupBlood, 2008
- International uniform response criteria for multiple myelomaLeukemia, 2006
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005